Stock Scorer

Cartesian Therapeutics, Inc. (RNAC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

-15M 0 15M 30M 45M Q3 '21: 24.4M Q4 '21: 29.9M Q1 '22: 34M Q2 '22: 39.3M Q3 '22: 20.7M Q4 '22: 16.8M Q1 '23: 5.9M Q2 '23: 5.2M Q3 '23: 6.6M Q4 '23: 8.3M Q1 '24: 5.8M Q2 '24: 33.4M Q3 '24: 387K Q4 '24: -759K Q1 '25: 1.1M Q2 '25: 298K Q3 '25: 452K Q4 '25: 947K Q1 '26: 78K Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -2M Q4 '21: 4.1M Q1 '22: 10.8M Q2 '22: 13.9M Q3 '22: -1.6M Q4 '22: -8.5M Q1 '23: -18.4M Q2 '23: -18.6M Q3 '23: -13.1M Q4 '23: -36.3M Q1 '24: -13.3M Q2 '24: 13.8M Q3 '24: -17.6M Q4 '24: -26.7M Q1 '25: -21.9M Q2 '25: -21.8M Q3 '25: -21.1M Q4 '25: -78.6M Q1 '26: -26.5M Q2 '26: -29.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: -17.9M Q4 '21: 12.2M Q1 '22: 28.8M Q2 '22: 8.6M Q3 '22: -7.9M Q4 '22: 13.2M Q1 '23: -21.7M Q2 '23: -11.4M Q3 '23: -9M Q4 '23: -177.7M Q1 '24: -56.8M Q2 '24: 13.8M Q3 '24: -24.2M Q4 '24: -10.3M Q1 '25: -17.7M Q2 '25: 15.9M Q3 '25: -35.9M Q4 '25: -92.6M Q1 '26: -39.2M Q2 '26: 15.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -10.7M Q4 '21: -31.5M Q1 '22: -11.9M Q2 '22: -12.3M Q3 '22: 4.4M Q4 '22: -11.8M Q1 '23: -8.8M Q2 '23: -9.9M Q3 '23: -9.2M Q4 '23: -23.3M Q1 '24: -15.9M Q2 '24: -14.4M Q3 '24: 13.7M Q4 '24: -7M Q1 '25: -23.1M Q2 '25: -17.5M Q3 '25: -15.6M Q4 '25: -17.7M Q1 '26: -22.1M Q2 '26: -21.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -10.9M Q4 '21: -31.7M Q1 '22: -12.3M Q2 '22: -12.4M Q3 '22: 3.9M Q4 '22: -12.1M Q1 '23: -8.9M Q2 '23: -9.9M Q3 '23: -9.2M Q4 '23: -23.4M Q1 '24: -16.5M Q2 '24: -16M Q3 '24: 7.5M Q4 '24: -7.7M Q1 '25: -24.2M Q2 '25: -20.1M Q3 '25: -16.9M Q4 '25: -18.2M Q1 '26: -22.2M Q2 '26: -21.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '20: 96.8M Q3 '20: 105.3M Q1 '21: 110.7M Q2 '21: 121.2M Q3 '21: 115.2M Q1 '22: 127.6M Q2 '22: 148.5M Q3 '22: 152.8M Q1 '23: 5.1M Q2 '23: 5.1M Q3 '23: 5.2M Q1 '24: 5.4M Q2 '24: 17.8M Q3 '24: 21.5M Q1 '25: 25.9M Q2 '25: 26.4M Q3 '25: 26M Q1 '26: 26.9M Q2 '26: 29.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q3 '20: -0.83 Q4 '20: -0.69 Q1 '21: -0.70 Q2 '21: -0.45 Q3 '21: -0.52 Q4 '21: -0.22 Q1 '22: 0.08 Q2 '22: 0.14 Q3 '22: 0.25 Q4 '22: 0.10 Q1 '23: -4.22 Q2 '23: -6.51 Q3 '23: -8.20 Q4 '23: -49.77 Q1 '24: -56.03 Q2 '24: -53.26 Q3 '24: -52.65 Q4 '25: -5.13 Q1 '26: -5.91 Q2 '26: -5.95 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for RNAC: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.